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624 The Journal of Thoracic and CardioBackground: Although a left ventricular assist device is often used to provide circula-
tory support until transplantation in severe heart failure, the mortality of long-term use
of left ventricular assist devices remains high. We have shown that hepatocyte growth
factor causes angiogenesis, antifibrosis, and antiapoptosis in the myocardium. Therefore,
gene therapy with hepatocyte growth factor–complementary DNA plasmids may en-
hance the chance of “bridge to recovery.” In this study, we performed gene therapy with
hepatocyte growth factor in the impaired goat heart with a left ventricular assist device.
Methods: Cardiac impairment was induced in 6 adult goats (56-65 kg) by ligation
of the coronary artery, and ventricular assist devices were installed. The hepatocyte
growth factor group (HGF; n  3) was administered human hepatocyte growth
factor–complementary DNA plasmid (2.0 mg) in the myocardium. The control
group (n 3) was similarly administered -galactosidase plasmid. Four weeks after
gene transfection, we attempted to wean all goats from the ventricular assist device.
Results: The myocardia transfected with human hepatocyte growth factor–complemen-
tary DNA contained human hepatocyte growth factor protein at levels as high as 1.0
0.3 ng/g tissue 3 days after transfection. After weaning from the ventricular assist
device, the HGF group showed good hemodynamics, whereas the control group showed
deterioration. The percentage of fractional shortening was significantly higher in the
HGF group than the control group (HGF vs control, 37.9% 1.7% vs 26.4% 0.3%,
respectively; P  .01). Left ventricular dilatation associated with myocyte hypertrophy
and fibrotic changes was detected in the control group but not in the HGF group.
Vascular density was markedly increased in the HGF group.
Conclusions: These results suggest that gene therapy with human hepatocyte growth
factor may enhance the chance of bridge to recovery in the impaired heart supported
with a ventricular assist device.
Cardiac transplantation continues to be the destination therapy for patientswith severe congestive heart failure (CHF). However, the overall applica-bility of cardiac transplantation is limited by a severe shortage of donors.1
For many patients with severe CHF, pharmacologic therapy is insufficient, and
revascularization or other surgical procedures are usually only palliative and do not
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Pgreatly reduce the overall ultimate mortality. Left ventricu-
lar assist devices (LVADs) are being used with greater
frequency to provide circulatory support until transplanta-
tion can be achieved. Unfortunately, many patients are now
being supported by these devices for several months and
even years. Although improvements in LVADs have re-
sulted in clinically meaningful survival benefits and an
improved quality of life for patients with severe CHF,
further improvements are needed.2 There have been several
recent reports of selected patients with end-stage CHF
whose recovery of cardiac function with the LVAD was
sufficient for the device to be explanted successfully.3-5
However, such patients constitute only a small percentage
of patients with LVADs. The long-term outcome of recov-
ery, the mechanism of recovery, and the identity of those
patients who are capable of recovery remain unclear. Be-
cause the number of patients with severe CHF continues to
increase, several efforts have been made to seek alterna-
tives, such as regeneration therapy.
Hepatocyte growth factor (HGF) is a potent angiogenic
agent with mitogenic, motogenic, and morphogenic effects
through its own specific receptor, c-Met, in various types of
cells, including myocytes.6,7 We have previously demonstrated
that HGF exerts antifibrotic and antiapoptotic effects in the
myocardium.8-10 Considering the pathogenic characteristics of
severe heart failure, such as progression of fibrosis, progression
of endothelial dysfunction, loss of functional capillaries, and
apoptosis-related loss of contractile mass,11,12 HGF might have
a beneficial effect in the impaired heart by attenuating these
remodeling processes.13,14
Therefore, gene transfection with the HGF gene may
enable a “bridge to recovery” in the impaired heart that is
supported with an LVAD. To investigate this possibility, we
performed gene therapy with HGF in impaired goat hearts
implanted with LVADs.
Materials and Methods
Preparation of Plasmid-Encoded Human HGF
Complementary DNA
A human HGF (hHGF) was inserted into the NotI site of the
pUC-SR expression vector plasmid as described elsewhere.15 In
this plasmid, expression of the hHGF complementary DNA
(cDNA) is regulated under the control of the SR promoter, which
is composed of a simian virus 40 polyadenylation sequence. The
purified plasmid containing 2000 g of hHGF-cDNA was recon-
stituted in sterile saline 2.0 mL and was directly injected into the
myocardium at 10 points with a 2.5-mL syringe and a 30-gauge
needle. The concentration of hHGF in the heart was determined by
enzyme-linked immunosorbent assay (ELISA) with anti-hHGF
antibody (Institute of Immunology, Tokyo, Japan). The antibody
against hHGF reacts only with hHGF and not with goat HGF. The
serum hHGF levels were also assessed with the same ELISA
system at 1, 3, 5, 7, 14, and 28 days after cDNA injection.
The Journal of ThoraciAnimal Model of Heart Impairment
Ten adult goats weighing 56 to 65 kg were used for this study. All
animals were treated humanely in compliance with the “Principles
of Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory An-
imal Resources and published by the National Institutes of Health
(Publication No. 86-23, revised 1985).
With goats under general anesthesia with isoflurane and nitrous
oxide, a thoracotomy was performed in the left fifth intercostal
space. Polyethylene catheters were inserted into the thoracic aorta
via the left carotid artery for measuring systemic blood pressure
(BP) and into the left jugular vein for intravenous infusion. Fiber-
optic pulmonary artery catheters (Oximetrix; Abbott Critical Care
Systems, North Chicago, Ill) were placed in the pulmonary artery
to allow mixed venous oxygen consumption (SvO2) and pulmonary
arterial pressure (PAP). Heart rate (HR) was continuously moni-
tored by electrocardiography.
For measuring aortic blood flow and bypass flow, electromag-
netic flowmeters (MF-2100; Nihon-Koden, Tokyo, Japan) were
placed in the ascending aorta and LVAD outflow cannulas. Aortic
blood flow was used as an index of native cardiac output, and the
ventricular assist device (VAD) assist ratio was calculated as
follows.
VAD assist ratio (%)  bypass flow (L/min)/(aortic blood flow
[L/min]  bypass flow [L/min])
The impaired heart was created by ligation of the left anterior
descending (LAD) coronary artery distal to its first diagonal
branch (Figure 1, A). After ligation, all goats underwent cardio-
genic shock and developed severe arrhythmias, such as ventricular
fibrillation and ventricular tachycardia. To maintain systemic cir-
culation and unload the left ventricle (LV), an LVAD (Toyobo,
Osaka, Japan) was installed extracorporeally between the left
atrium and the descending aorta. A 1⁄2-inch vinyl chloride inflow
cannula with multiple side holes was used for blood drainage, and
a 1⁄2-inch vinyl chloride outflow cannula with a 12-mm woven
graft (Meadox, Oakland, NJ) was used for blood return. This
outflow cannula, sutured onto the descending aorta and inflow
cannula, was inserted into the left atrium without cardiopulmonary
bypass (Figure 1, B) after systemic heparinization (300 U/kg;
intravenous injection). A right VAD (Toyobo) was installed ex-
tracorporeally between the right atrium and the pulmonary trunk in
the same procedure (Figure 1, B). The goats were randomly
divided into 2 groups. In the HGF group, hHGF-cDNA plasmid—
2.0 mg of hHGF-cDNA in 2.0 mL of plasmid solution—was
injected with 30-gauge needles into the myocardium at 10 points
of the ischemic area of the LV wall (Figure 1, A). There were no
changes in the hemodynamic conditions associated with the injec-
tion of hHGF-cDNA plasmid, and there were no obvious adverse
effects, such as anaphylactic reaction, in the goats throughout this
experiment. In the control group, an equivalent volume of -ga-
lactosidase plasmid was injected in the same procedure. The chest
was then closed, and goats were allowed to recover from anesthe-
sia. To detect hHGF protein in the treated myocardium, 2 goats
from each group were killed 3 days after the cDNA injection. In
another 3 goats from each group, systemic circulation was subse-
quently maintained under biventricular assist devices (BVADs) for
c and Cardiovascular Surgery ● Volume 130, Number 3 625
Cardiopulmonary Support and Physiology Shirakawa et al
CSP
4 weeks. Anticoagulation was performed 2 days after surgery.
Warfarin sodium was administered with the target of the interna-
tional normalized ratio, which ranged between 2.5 and 3.5. No
platelet antiaggregation drugs were administrated.
Assessment of Cardiac Function
We estimated the changes of cardiac function by means of 3-
dimensional digital sonomicrometry (Sonometrics Corp, Ontario,
Canada).16 Two ultrasonic crystals were implanted in the endocar-
dium parallel to the short axis at the level of the papillary muscle at the
time of operation (Figure 1, C). These crystals were placed in the
anterior wall and its opposite site to assess myocardial contractility in
the distribution of the LAD coronary artery. The LV dimension at
end-diastole (LVDd) and end-systole (LVDs) were determined by
Figure 1. Animal model of the impaired heart and experim
hearts by ligating the left anterior descending coronary
encoding hHGF cDNA or -galactosidase into the myoc
goats with impaired hearts. C, Sites of ultrasonic crystals
parallel to the short axis of the left ventricle at the levelsimultaneously measured left ventricular pressure.
626 The Journal of Thoracic and Cardiovascular Surgery ● SeptThe LV percentage of fractional shortening (%FS) was calcu-
lated as follows:
%FS  (LVDd  LVDs)/LVDd  100
Before and after ligation of the LAD coronary artery and
at 1, 2, 3, and 4 weeks after gene transfection, we measured
%FS and cardiac output with the BVAD turned off for short periods.
VAD Off Test
Four weeks after gene transfection, an attempt was made to wean
all goats from BVAD. After systemic heparinization (300 U/kg;
intravenous injection), the BVAD was turned off. At 5, 15, and 30
minutes after turning off the BVAD, we measured HR, BP, SvO2,
l design. A, Creation of myocardial infarction in adult goat
ry provided direct administration (crosses) of plasmids
m. B, Biventricular assist devices were installed in all
ultrasonic crystals were implanted in the endocardium
apillary muscle at the time of operation.enta
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PHistologic Analysis
Four weeks after plasmid administration and after the VAD-off
test, all goats were killed with an overdose of sodium pentobarbi-
tal, and the hearts were excised. The hearts were cut at the short
axis into 5 pieces, and LV myocardium specimens were fixed with
10% buffered formalin and embedded in paraffin. A few serial
sections from each specimen were cut into 5-m-thick slices and
stained with hematoxylin and eosin for histologic examination and
measurement of cardiomyocyte cell diameter or with azan-
trichrome stain to assess the collagen content. The proportion of
the fibrosis-occupying area at the border area neighboring the
infarct area was measured on 10 randomly selected fields, and the
result was expressed as the percentage of fibrosis.
To label vascular endothelial cells so that the blood vessels
could be counted in the border area neighboring the infarct area,
immunohistochemical staining of von Willebrand factor–related
antigen was performed according to a modified protocol. We used
enhanced polymer one-step staining (EPOS)-conjugated antibod-
ies against von Willebrand factor–related antigen coupled with
horseradish peroxidase (EPOS anti–human von Willebrand factor/
horseradish peroxidase; DAKO, Carpinteria, Calif) as primary
antibodies. The stained vascular endothelial cells were counted as
vascular density under a light microscope at 200 magnification
by using at least 10 randomly selected fields per section. The result
was expressed as the number of blood vessels per square
millimeter.
Computer appraisals of pathology (cell diameter, percentage of
fibrosis, and vascular density) were performed with a Macintosh
computer (Apple Inc, Cupertino, Calif) by using a public domain
image program developed at the US National Institutes of Health.
Statistical Analysis
All data are expressed as mean  SD. Intergroup comparisons
were made with analysis of variance and the unpaired Student t
test. All analyses were performed with StatView (version 5.0;
Abacus Concepts, Inc, Berkeley, Calif).
Results
In Vivo HGF Gene Transfection
Three days after transfecting hearts with hHGF-cDNA plas-
mid, we measured the hHGF protein content in the myo-
cardial samples obtained from the cDNA-injected area by
an ELISA assay. The myocardia transfected with the hHGF-
cDNA contained hHGF protein at levels as high as 1.0 
TABLE 1. Hemodynamic conditions under mechanical circ
Before MI After MI
Heart rate (beats/min)
HGF group 98 2 59  1 14
Control group 86 10 62 10 14
Mean AoP (mm Hg)
HGF group 100 10 59 8 8
Control group 96 6 60  10 8
Data are expressed as mean  SD. MI, Myocardial infarction; HGF, hepa0.3 ng/g tissue on the third day after transfection. In con-
The Journal of Thoracitrast, hHGF was not detected in the myocardia of the control
group animals. The serum hHGF levels were not detected in
either group throughout the experiment.
Animal Condition and Systemic Hemodynamic Data
Just after infarction, severe low-output syndrome and car-
diogenic shock developed in all goats. Native cardiac out-
puts decreased approximately 20 or 30 mL · kg1 · min1.
With BVAD support, all animals were maintained in good
condition, and the HR and BP on unloaded conditions by
VAD support did not differ between the 2 groups through-
out this experiment (Table 1). The VAD assist ratio was
maintained at approximately 70% throughout the experi-
ment, and this ratio did not differ markedly between groups
(Figure 2, A). However, at 4 weeks after the gene transfec-
tion, the cardiac output in the HGF group was significantly
higher than that in the control group (85.0  1.4 mL · kg1
· min1 in the HGF group vs 64.6  6.0 mL · kg1 · min1
in the control group; P  .01; Figure 2, B).
Assessment of Cardiac Function
After infarction, the %FS was markedly decreased com-
pared with the baseline values in both groups, and the
degree of deterioration did not differ between groups. The
%FS recovered gradually in the 2 groups after gene trans-
fection. However, the %FS improvement in the HGF group
was significantly larger than that in the control group. The
%FS in the HGF group 4 weeks after gene transfection was
significantly recovered compared with the control group
(37.9%  1.7% in the HGF group vs 26.4%  0.3% in the
control group; P  .01; Figure 3).
VAD Off Test
Four weeks after gene transfection, we performed a VAD-
off test (Figure 4). HR was steadily increased and BP was
steadily decreased in the control group on loaded condition
after the BVAD was turned off, but in the HGF group, these
parameters remained stable and did not deteriorate. The
SvO2 and the PAP of the control group also deteriorated
relative to those of the HGF group. Cardiac output was
significantly increased in the HGF group compared with the
ory arrest
1 wk 2 wk 3 wk 4 wk
5 146 4 131  9 121  17 118  17
7 147 4 134  3 113  28 90  28
3 82 5 87  5 94  5 91 5
7 86 9 97  10 93  10 96  3
e growth factor; AoP, aortic pressure.ulat
3 d
5
0
2
0control group 30 minutes after weaning from VAD (80.1 
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· kg1 · min1 in the control group; P  .05; Figure 4). In
the control group, LVDd was significantly increased rela-
tive to that in the HGF group 30 minutes after weaning from
VAD (35.8  1.6 mm in the HGF group vs 46.9  0.1 mm
in the control group; P  .05; Figure 4).
Histologic Assessment
Macroscopic autopsy findings of expired hearts revealed
that LV dilatation was markedly suppressed in the HGF
group relative to that in the control group, although necrotic
changes and scar formation of the anterior wall were rec-
ognized in both groups (Figure 5, A and B). Azan staining of
the myocardium in the neighborhood of the infarcted area
revealed that fibrous change was also suppressed in the
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monds and the control group by circles. Data are presented as
mean  SD. *P < .01 versus the control group.
628 The Journal of Thoracic and Cardiovascular Surgery ● SeptHGF group compared with that in the control group (Figure
5, C and D). The percentage of fibrosis was significantly
reduced in the HGF group compared with the control group
(13.9%  1.7% in the HGF group vs 22.3%  1.3% in the
control group; P  .01; Figure 6, A).
Hematoxylin and eosin staining of the border zone re-
vealed hypertrophic change of cardiomyocytes in the con-
trol group, but not in the HGF group (Figure 5, E and F).
The cell diameter was significantly smaller in the HGF
group than in the control group (39.6  0.5 m in the HGF
group vs 54.4  0.6 m in the control group; P  .01;
Figure 6, B).
Vascular density was examined in the border zone of the
infarct area (Figure 5, G and H). Vascular density was signif-
icantly higher in the HGF group than in the control group (35.2
 2.1 vessels per field in the HGF group vs 24.5 2.7 vessels
per field in the control group; P  .05; Figure 6, C).
Discussion
The major findings of this study were as follows: (1) LV
unloading by VAD alone could not achieve sufficient sup-
pression of cardiac remodeling after myocardial infarction,
and (2) gene transfection with HGF-cDNA plasmids atten-
uated cardiac remodeling in the impaired heart under me-
chanical unloading with VAD and achieved markedly better
improvement of cardiac function than that by VAD alone,
thus suggesting its potential use as a bridge to recovery.
Recently, several studies of regenerative therapy with
gene therapy or cell transplantation have reported the effect
on protection of cardiomyocytes and improvement of car-
diac function in the impaired heart.17-20 However, such
therapies require time to take effect and are not able to
control heart failure immediately after treatment. VAD may
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Poptimal environment for myocardial recovery, along with
ventricular unloading.2-5,21-23 We therefore propose a com-
bination therapy consisting of gene therapy and VAD as a
new strategy for the treatment of severe heart failure. VAD
provides sufficient time and suitable circumstances for myo-
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HGF is a potent angiogenic factor, and we have started
its clinical application at Osaka University Hospital for
patients with arteriosclerosis obliterans.24 Furthermore,
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CSPvarious physiological activities, including antifibrotic and
cardiotrophic activities.6-9,25,26 Therefore, we believe that
HGF has an advantage for promoting myocardial regener-
ation. In the chronic phase of myocardial infarction, the
progression of cardiac remodeling with reduced cardiac
Figure 5. Histologic findings of the heart 4 weeks afte
short-axis area of the left ventricle. C and D, Azan-trich
infarcted and normal area (bar  100 m; original ma
of the myocardium of the border zone (bar  100 m;
staining by von Willebrand antibody (bar 100 m; ori
antibody–positive endothelial cells. A, C, E, and G are frfunction is responsible for interstitial fibrosis and for the
630 The Journal of Thoracic and Cardiovascular Surgery ● Septapoptosis of the cardiomyocytes. In particular, fibrosis re-
mote from the infarcted area is considered to be the major
cause of ventricular remodeling in ischemic cardiomyopa-
thy. In this study, neoangiogenesis was induced and fibrosis
was suppressed in the peri-infarcted area by HGF gene
e transfection. A and B, Macroscopic findings of the
e staining of the myocardium in the border zone of the
ation, 100). E and F, Hematoxylin and eosin staining
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Pduring cardiac remodeling have been identified.27 Trans-
forming growth factor- and angiotensin II are believed to
play an important role in the pathogenesis of fibrosis.28-30
These molecules are the negative regulators of local HGF
production in various cell types.7-9 In this study, increased
local HGF expression may have prevented myocardial fi-
brosis, possibly by inhibiting the production of such mole-
cules, as previously reported.6-10 Regarding delivery of
HGF, we did not use any vector for gene therapy in this
study: we have already reported that direct administration of
the HGF-cDNA plasmid is enough for local and continuous
intramural delivery of HGF to enhance angiogenesis and
cardiac function in the infarct myocardium.6-8,24,25 It is
speculated that native HGF also plays an important role as
a cardioprotective factor, but native HGF was insufficient
for attenuation of cardiac remodeling in this experiment.
Gene transfection of hHGF plasmid also supported the
cardioprotective role of native HGF, and thus less continu-
ously expressed protein could be sufficient to induce angio-
genesis and support the subsequent recovery of regional
cardiac function.13,14 Moreover, HGF acts as a paracrine
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zone (mean  SD). C, Vascular density: data are exprgrowth factor, and its production by the administration of
The Journal of ThoraciHGF-cDNA plasmid in the myocardium continues for ap-
proximately 14 days. Its local synthesis without viral vec-
tors might safeguard against adverse effects while remain-
ing undetected in the serum HGF level during gene therapy.
Thus, our results offer promise for clinical applications.
To the best of our knowledge, this is the first report to
demonstrate the effectiveness of regenerative therapy in the
impaired heart with LVAD support, and the protocol of this
study could be used as one of the new therapeutic strategies
for severe heart failure. However, several limitations of this
study must be considered before clinical application. First,
because of limitations of the experimental protocol, we were
not able to clarify the efficacy of this method with respect to
scar thinning and expansion of the impaired myocardium in
the chronic phase. When loss of the contractile mass is
markedly increased, such as in patients with dilated cardio-
myopathy, regeneration of cardiomyocytes is insufficient to
increase the contractile function, even with HGF gene trans-
fection. Thus, a method of supplementing the contractile
mass, such as cellular cardiomyoplasty, may be needed to
increase treatment efficacy. Second, because of the lack of
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the long-term outcome of the effect of HGF is also unclear.
In the setting of this experiment, after coronary ligation,
severe arrhythmias such as ventricular tachycardia and fi-
brillation frequently occurred. We implanted right VADs to
maintain the VAD flow and systemic circulation. To address
these problems, further studies are needed.
In conclusion, we have demonstrated the possible thera-
peutic value of suppression of cardiac remodeling by hHGF
gene transfection in the impaired heart under LVAD. Our
results suggest that, in the setting of acute myocardial in-
farction causing cardiogenic shock, combined therapy with
HGF gene therapy and LVAD can increase the chance of a
bridge to recovery in the severely impaired heart under
LVAD.
We thank Akiko Nishimura and Shigeru Matsumi for their
excellent technical assistance.
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